Antipsychotic medication and oxidative cell stress: A systematic review

Journal of Clinical Psychiatry

Volumn 72, Issue 3, 2011, Pages 273-285

  Lepping, Peter ^a,b   Delieu, John ^c   Mellor, Richard ^b   Williams, John H H ^d   Hudson, Peter R ^b   Hunter Lavin, Claire ^d  

^a GLYNDWR UNIVERSITY   (United Kingdom)

^b BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

^c BANGOR UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF CHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BROMPERIDOL; CATALASE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HALOPERIDOL; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN ANTIBODY; HOMOCYSTEINE; HYDROGEN PEROXIDE; MALONALDEHYDE; NEUROLEPTIC AGENT; OLANZAPINE; OXYGEN; POLYUNSATURATED FATTY ACID; PROTEIN ANTIBODY; QUETIAPINE; REACTIVE OXYGEN METABOLITE; RISPERIDONE; SULPIRIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIORIDAZINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE;

CELL STRESS; EMBASE; HUMAN; IMMUNE RESPONSE; MEDLINE; NEUROPROTECTION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PSYCINFO; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

EID: 79953044040     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09r05268yel     Document Type: Review

References (74)

1. National Institute for Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London, United Kingdom: National Institute for Clinical Excellence; 2002.
2. Li XM, Chlan-Fourney J, Juorio AV, et al. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J Neurosci Res. 1999;56(1):72-75. doi:10.102/(SICI)1097-4547(190401)56:1〈72:AID-JNR9〉3.0.CO;2-0 PubMed (Pubitemid 29190618)
3. Wang H, Xu H, Dyck LE, et al. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res. 2005;81(4):572-580. doi:10.102/jnr.20570 PubMed
4. Xu H, Wang H, Zhuang L, et al. Demonstration of an anti-oxidative stress mechanism of quetiapine: implications for the treatment of Alzheimer's disease. FEBS J. 2008;275(14):3718-3728. doi:10.1/j.1742-4658.208.06519.x PubMed
5. Lieberman JA. Neuroprotection: a new strategy in the treatment of schizophrenia. Neurobiological basis of neurodegeneration and neuroprotection. CNS Spectr. 2007;12(suppl 18):4-6. PubMed
6. Ng F, Berk M, Dean O, et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11(6):851-876. doi:10.1017/S14614570708401 PubMed
7. Delieu JM, Badawoud M, Williams MA, et al. Antipsychotic drugs result in the formation of immature neutrophil leucocytes in schizophrenic patients. J Psychopharmacol. 2001;15(3):191-194. doi:10.17/026981010150306 PubMed (Pubitemid 32808253)
8. Delieu JM, Horobin RW, Duguid JK. Formation of immature neutrophil leucocytes in schizophrenic patients treated with various antipsychotic drugs: comparisons and predictions. J Psychopharmacol. 2006;20(6):824-828. doi:10.17/026981060612 PubMed (Pubitemid 44622747)
9. Schyve PM, Smithline F, Meltzer HY. Neuroleptic-induced prolactin level elevation and breast cancer: an emerging clinical issue. Arch Gen Psychiatry. 1978;35(11):1291-1301. PubMed
10. Brakoulias V, Bannan E, Cohen P, et al. Amisulpride and cardiomyopathy. Aust N Z J Psychiatry. 2005;39(8):738. PubMed
11. Williams DP, O'Donnell CJ, Maggs JL, et al. Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro. Chem Res Toxicol. 2003;16(10): 1359-1364. doi:10.1021/tx034035z PubMed (Pubitemid 37315224)
12. Hägg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs. 2002;16(11):765-776. PubMed doi:10.2165/023210-2021610-05
13. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001;62(suppl 27):15-26, discussion 40-41. PubMed
14. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(suppl 4):8-13. PubMed
15. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med. 2005;118(suppl 2):15S-22S. PubMed
16. Lepping P, Mukandan J, Poole R. Neuroleptic malignant syndrome and catatonia. Prog Neurol Psychiatry. 2007;11:9-14.
17. Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111(11):1448-1454. doi:10.161/01.CIR.0158483. 13093.9D PubMed (Pubitemid 40396812)
18. Fischer V, Haar JA, Greiner L, et al. Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis. Mol Pharmacol. 1991;40(5):846-853. PubMed
19. Bhana N, Foster RH, Olney R, et al. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-161. doi:10.2165/03495-20161010-01 PubMed (Pubitemid 32108327)
20. Jiang F, Drummond GR, Dusting GJ. Suppression of oxidative stress in the endothelium and vascular wall. Endothelium. 2004;11(2):79-88. doi:10.1080/106232049048260 PubMed (Pubitemid 39207181)
21. Williams JH, Ireland HE. Sensing danger - Hsp72 and HMGB1 as candidate signals. J Leukoc Biol. 2008;83(3):489-492. doi:10.189/jlb.0607356 PubMed (Pubitemid 351966855)
22. Wright BH, Corton JM, El-Nahas AM, et al. Elevated levels of circulating heat shock protein 70 (Hsp70) in peripheral and renal vascular disease. Heart Vessels. 2000;15(1):18-22. doi:10.107/s03807043 PubMed
23. Xu Q, Schett G, Li C, et al. Mechanical stress-induced heat shock protein 70 expression in vascular smooth muscle cells is regulated by Rac and Ras small G proteins but not mitogen-activated protein kinases. Circ Res. 2000;86(11):1122-1128. PubMed
24. Tsiftsoglou AS, Tsamadou AI, Papadopoulou LC. Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. Pharmacol Ther. 2006;111(2):327-345. doi:10.1016/j.pharmthera.205.10. 017 PubMed (Pubitemid 43832008)
25. Hunter-Lavin C, Hudson PR, Mukherjee S, et al. Folate supplementation reduces serum hsp70 levels in patients with type 2 diabetes. Cell Stress Chaperones. 2004;9(4):344-349. doi:10.1379/CSC-28R.1 PubMed
26. Pockley AG, Wu R, Lemne C, et al. Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension. 2000;36(2):303-307. PubMed
27. Davies EL, Bacelar MM, Marshall MJ, et al. Heat shock proteins form part of a danger signal cascade in response to lipopolysaccharide and GroEL. Clin Exp Immunol. 2006;145(1):183-189. doi:10.1/j.1365-249.206.03109.x PubMed (Pubitemid 43893948)
28. Guzhova I, Kislyakova K, Moskaliova O, et al. In vitro studies show that Hsp70 can be released by glia and that exogenous Hsp70 can enhance neuronal stress tolerance. Brain Res. 2001;914(1-2):66-73. doi:10.1016/S06-893(01)0274-3 PubMed
29. Hunter-Lavin C, Davies EL, Bacelar MM, et al. Hsp70 release from peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2004;324(2):511-517. doi:10.1016/j.brc.204.09.075 PubMed (Pubitemid 39345547)
30. Ireland HE, Leoni F, Altaie O, et al. Measuring the secretion of heat shock proteins from cells. Methods. 2007;43(3):176-183. doi:10.1016/j.ymeth.207. 06.01 PubMed (Pubitemid 47499081)
31. Hennekens CW. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry. 2007;68(suppl 4):4-7.
32. Khan MM, Evans DR, Gunna V, et al. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res. 2002;58(1):1-10. doi:10.1016/S0920-964(01)034-6 PubMed (Pubitemid 35287278)
33. Neeman G, Blanaru M, Bloch B, et al. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry. 2005;162(9):1738-1740. doi:10.176/api.ajp.162.9.1738 PubMed (Pubitemid 41318246)
34. Ramchand CN, Davies JI, Tresman RL, et al. Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients. Prostaglandins Leukot Essent Fatty Acids. 1996;55(1-2):27-31. doi:10.1016/S0952-3278(96)90142-8 PubMed (Pubitemid 26321115)
35. Zhang XY, Tan YL, Cao LY, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res. 2006;81(2-3):291-300. doi:10.1016/j.schres.205.10.01 PubMed (Pubitemid 43107705)
36. Bonelli RM, Hofmann P, Aschoff A, et al. The influence of psychotropic drugs on cerebral cell death: female neurovulnerability to antipsychotics. Int Clin Psychopharmacol. 2005;20(3):145-149. doi:10.1097/04850-205050-04 PubMed (Pubitemid 40571512)
37. Abdalla DS, Monteiro HP, Oliveira JA, et al. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem. 1986;32(5):805-807. PubMed
38. Akyol Ö, Herken H, Uz E, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(5):995-1005. doi:10.1016/S0278-5846(02)020-8 PubMed (Pubitemid 35245568)
39. Evans DR, Parikh VV, Khan MM, et al. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids. 2003;69(6):393-399. doi:10.1016/j.plefa.203.08.010 PubMed (Pubitemid 37464048)
40. Kim JJ, Lee SJ, Toh KY, et al. Identification of antibodies to heat shock proteins 90 kDa and 70 kDa in patients with schizophrenia. Schizophr Res. 2001;52(1-2):127-135. doi:10.1016/S0920-964(0)091-8 PubMed (Pubitemid 32947056)
41. Linday LA, Pippenger CE, Howard A, et al. Free radical scavenging enzyme activity and related trace metals in clozapine-induced agranulocytosis: a pilot study. J Clin Psychopharmacol. 1995;15(5):353-360. doi:10.1097/04714-19510-08 PubMed
42. Bindoli A, Rigobello MP, Cavallini L, et al. Decrease of serum malondialdehyde in patients treated with chlorpromazine. Clin Chim Acta. 1987; 169(2-3):329-332. doi:10.1016/09-8981(87)9034-2 PubMed (Pubitemid 18007055)
43. Gama CS, Salvador M, Andreazza AC, et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):512-515. doi:10.1016/j.pnpbp.205.1.09 PubMed
44. Jeding I, Evans PJ, Akanmu D, et al. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol. 1995;49(3):359-365. doi:10.1016/06-2952(94)0424-K PubMed
45. Kropp S, Kern V, Lange K, et al. Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsychiatry Clin Neurosci. 2005;17(2):227-231. PubMed
46. Pai BN, Janakiramaiah N, Gangadhar BN, et al. Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol Psychiatry. 1994;36(7):489-491. doi:10.1016/06-323(94)90648-3 PubMed
47. Peet M, Laugharne J, Rangarajan N, et al. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res. 1995;29(3):227-232. doi:10.1016/02-3956(95)01-L PubMed
48. Sarandol A, Kirli S, Akkaya C, et al. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1164-1169. doi:10.1016/j.pnpbp.207.03.08 PubMed (Pubitemid 47081301)
49. Arolt V, Rothermundt M, Wandinger KP, et al. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry. 2000;5(2):150-158. doi:10.1038/sj.mp.40650 PubMed (Pubitemid 30229429)
50. Kamińska T, Szuster-Ciesielska A, Wysocka A, et al. Serum cytokine level and production of reactive oxygen species (ROS) by blood neutrophils from a schizophrenic patient with hypersensitivity to neuroleptics. Med Sci Monit. 2003;9(7):CS71-CS75. PubMed
51. Yao JK, Reddy R, McElhinny LG, et al. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res. 1998; 32(6):385-391. doi:10.1016/S02-3956(98)028-4 PubMed (Pubitemid 28491244)
52. Zhang X, Zhou D, Cao L, et al. Pharmacokinetic profile of an oral loading dose of divalproex sodium during acute alcohol withdrawal. J Clin Psychopharmacol. 2006;26:104-105.
53. Skoblenick KJ, Castellano JM, Rogoza RM, et al. Translocation of AIF in the human and rat striatum following protracted haloperidol, but not clozapine treatment. Apoptosis. 2006;11(5):663-672. doi:10.107/s10495-06-5698-6 PubMed (Pubitemid 43876837)
54. Zhang XY, Zhou DF, Su JM, et al. The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J Clin Psychopharmacol. 2001;21(1):85-88. doi:10.1097/04714- 201020-015 PubMed (Pubitemid 32096755)
55. Kim YK, Suh IB, Kim H, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry. 2002;7(10):1107-1114. doi:10.1038/sj.mp.401084 PubMed (Pubitemid 36044270)
56. Lieber MR, Lange Y, Weinstein RS, et al. Interaction of chlorpromazine with the human erythrocyte membrane. J Biol Chem. 1984;259(14):9225-9234. PubMed
57. Rudolf S, Peters M, Rothermundt M, et al. The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon- gamma in vitro. Neuropsychobiology. 2002;46(4):180-185. doi:10.159/067807 PubMed (Pubitemid 36173365)
58. Szuster-Ciesielska A, Słotwińska M, Stachura A, et al. Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers. Arch Immunol Ther Exp (Warsz). 2004;52(1):59-67. PubMed
59. Arvindakshan M, Sitasawad S, Debsikdar V, et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry. 2003;53(1):56-64. doi:10.1016/S06-323(02)0143-9 PubMed (Pubitemid 36050936)
60. Gross A, Joffe G, Joutsiniemi SL, et al. Decreased production of reactive oxygen species by blood monocytes caused by clozapine correlates with EEG slowing in schizophrenic patients. Neuropsychobiology. 2003;47(2):73-77. doi:10.159/07012 PubMed (Pubitemid 36469843)
61. Joffe G, Nyberg P, Gross A, et al. Clozapine-induced decrease in the production of reactive oxygen metabolites by monocytes in vitro may predict clinical response to clozapine in treatment-resistant schizophrenia. Hum Psychopharmacol. 1999;14(3):203-209. doi:10.102/(SICI)109-107(1904)14:33.0.CO;2- 1 (Pubitemid 29237746)
62. Dakhale G, Khanzode S, Khanzode S, et al. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology. 2004;49(4):205-209. doi:10.159/07368 PubMed (Pubitemid 38594573)
63. Fehsel K, Loeffler S, Krieger K, et al. Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J Clin Psychopharmacol. 2005;25(5):419-426. doi:10.1097/01.jcp.01768. 42640.fe PubMed (Pubitemid 41368363)
64. Joffe G, Nyberg P, Gross A, et al. Is there an association between the effects of clozapine on the production of reactive oxygen metabolites by blood monocytes and clinical outcome in neuroleptic-resistant schizophrenia? Hum Psychopharmacol. 1998;13(4):231-237. doi:10.102/(SICI)109-107(19806)13: 4〈231:AID-HUP976〉3.0.CO;2-J
65. Zhang XY, Zhou DF, Cao LY, et al. The effect of risperidone treatment on superoxide dismutase in schizophrenia. J Clin Psychopharmacol. 2003;23(2):128-131. doi:10.1097/04714-203040-04 PubMed (Pubitemid 36368789)
66. Atmaca M, Tezcan E, Kuloglu M, et al. The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin Neurosci. 2005;59(6):652-656. doi:10.1/j.140-1819.205.01432.x PubMed (Pubitemid 43151656)
67. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand. 1994;89(5):346-351. doi:10.1/j.160-047.194.tb01527.x PubMed (Pubitemid 24157957)
68. Hinze-Selch D, Becker EW, Stein GM, et al. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology. 1998;19(2):114-122. doi:10.1016/S0893- 13X(98)06-2 PubMed (Pubitemid 28288437)
69. Hinze-Selch D, Deuschle M, Weber B, et al. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl). 2000;149(2):163-169. doi:10.107/s021390351 PubMed (Pubitemid 30238954)
70. Pollmächer T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol. 1996;16(5):403-409. doi:10.1097/04714-19610-01 PubMed (Pubitemid 26352672)
71. Mahadik SP, Pillai A, Joshi S, et al. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry. 2006;18(2):119-131. doi:10.1080/095402606058193 PubMed (Pubitemid 43791675)
72. Schwarz MJ, Riedel M, Gruber R, et al. Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Am J Psychiatry. 1999;156(7):1103-1104. PubMed
73. Dietrich-Muszalska A, Olas B. Isoprostenes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry. 2009;10(1):27-33. doi:10.1080/1562970701361263 PubMed
74. Ahmed N, Babaei-Jadidi R, Howell SK, et al. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia. 2005;48(8):1590-1603. (Pubitemid 41175513)